Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11135772 | 0.91 | CA2 (0.43) | CA2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27480718 | 0.89 | MEN1 (0.62) | CA2MEN1KMT2ACYP2D6HTR2A | |
| SCHEMBL2763119 | 0.83 | KMT2A (0.56) | CA2KMT2ANPC1RAB9AHTR2A | |
| SCHEMBL13084751 | 0.81 | NPC1 (0.49) | MEN1KMT2ANPC1RAB9ACYP2D6 | |
| SCHEMBL7498931 | 0.81 | HDAC3 (0.50) | MEN1KMT2ANPC1RAB9ACYP2D6 | |
| SCHEMBL19754954 | 0.80 | KMT2A (0.53) | MEN1KMT2ANPC1RAB9ACYP2D6 | |
| SCHEMBL10583597 | 0.78 | HTR2A (0.76) | CYP2D6HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7498927 | 0.78 | NPC1 (0.52) | MEN1KMT2ANPC1RAB9ACYP2D6 | |
| SCHEMBL27567003 | 0.77 | GAA (0.53) | MEN1KMT2ANPC1RAB9AHRH3 | |
| Hydrochloric Acid SCHEMBL10585887 | 0.77 | HTR2A (0.74) | CYP2D6HTR2AHTR2CHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261208-A1 | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives | Aventisub II Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261207-A1 | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives | Aventisub II Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-1953142-A1 | Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives | Aventis Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| CN-1275916-C | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMA INC (US) | 2006-09-20 | — | — | CN | disclosed |
| CN-1603291-A | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMA INC (US) | 2005-04-06 | — | — | CN | disclosed |
| CN-1168717-C | Novel intermediates for the preparation of antihistaminic piperidine derivatives | Ĭ���ҩ�﹫˾ | 2004-09-29 | — | — | CN | disclosed |
| US-6777555-B2 | 3-(OPTIONALLY HYDROXYL)-4-(CYCLOPROPYLCARBONYL)-CUMENE INTERMEDIATE | MERRELL PHARMACEUTICALS, INC. | 2004-08-17 | — | — | US | disclosed |
| CN-1159277-C | New intermediate for preparation of anti-histamine piperidine derivatives | Ĭ���ҩ�﹫˾ | 2004-07-28 | — | — | CN | disclosed |
| US-20030220496-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6566526-B2 | Intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2003-05-20 | — | — | US | disclosed |
| US-20010021791-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | disclosed |
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-06 | — | — | US | disclosed |
| US-20010018521-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-08-30 | — | — | US | disclosed |
| US-6242606-B1 | REACTING A A,A-DIMETHYLPHENYLACETIC ACID AMIDE WITH A W-HALO COMPOUND PRODUCES W'-HALO-A-KETO-A,A-DIMETHYLPHENYLACETIC ACID AMIDE AND REACTING IT WITH A PIPERIDINE COMPOUND; 2-(4-(4-CHLORO-BUTYRYL)-PHENYL)-2-METHY-PROPIONIC ACID | MERRELL PHARMACEUTICALS INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010000038-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | CHATTEM INC. | 2001-03-15 | — | — | US | disclosed |
| CN-1274711-A | New intermediate for preparation of anti-histamine piperidine derivatives | MERRELL DOW PHARMA (US) | 2000-11-29 | — | — | CN | disclosed |
| US-6147216-A | Intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 2000-11-14 | — | — | US | disclosed |
| CN-1128987-A | Novel intermediates for the preparation of antihistaminic piperidine derivatives | MERRELL DOW PHARMA (US) | 1996-08-14 | — | — | CN | disclosed |
| EP-0705245-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000480-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000038-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CA2 132/4885MEN1 2722/4885KMT2A 1588/4885 |
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CA2 237/4885MEN1 2716/4885KMT2A 2070/4885 |
| US-20030220496-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CA2 132/4885MEN1 2722/4885KMT2A 1588/4885 |
| US-20010021791-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CA2 394/4885MEN1 2111/4885KMT2A 2014/4885 |
| US-20010018521-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CA2 273/4885MEN1 2708/4885KMT2A 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.